Financial Performance - The company achieved a net profit attributable to shareholders of 45,455,341.19 RMB in 2022, a decrease of 87.44% compared to 361,900,881.01 RMB in 2021[6]. - Total revenue for 2022 was 12,951,443,198.74 RMB, representing a year-on-year increase of 4.76% from 12,363,270,871.06 RMB in 2021[23]. - The total profit for 2022 was 261 million RMB, a decrease of 59.45% compared to the previous year[63]. - The net profit attributable to the parent company was 45 million RMB, down 87.44% year-on-year[63]. - The basic earnings per share for 2022 were 0.04 RMB, down 88.89% from 0.36 RMB in 2021[24]. - The weighted average return on equity decreased to 1.01% in 2022, down 7.33 percentage points from 8.34% in 2021[24]. - The net profit attributable to shareholders decreased significantly, with a reduction of 21.37% in net assets compared to the beginning of the period, primarily due to the expiration of perpetual bonds and profit distribution impacts[25]. - The company reported a significant impairment loss of 261,835,900 RMB on certain health real estate projects, impacting overall profitability[24]. Cash Flow and Assets - The net cash flow from operating activities decreased by 85.43% to 998,095,209.30 RMB in 2022, down from 6,848,228,115.50 RMB in 2021[23]. - The company's total assets at the end of 2022 were 58,473,809,904.37 RMB, a decrease of 4.79% from 61,415,459,283.31 RMB at the end of 2021[23]. - The net cash flow from operating activities decreased by 85.43% year-on-year, mainly due to reduced sales collections in the health real estate business[25]. - The net assets attributable to shareholders decreased by 21.37% to 3,716,705,398.06 RMB at the end of 2022, compared to 4,727,128,835.89 RMB at the end of 2021[23]. Business Segments Performance - In 2022, the pharmaceutical business generated revenue of 511 million RMB, while the cosmetics segment achieved revenue of 1.969 billion RMB, representing a year-on-year growth of 31.68%[36][37]. - The cosmetics brand Yilian achieved revenue of 710 million RMB, a year-on-year increase of 10.32%, while the brand Aierbo achieved 1.058 billion RMB, growing by 42.25%[37]. - The cosmetics segment generated a revenue of 1.97 billion RMB with a gross margin of 60.97%[73]. - The pharmaceutical segment reported a revenue of 511 million RMB with a gross margin of 53.00%[73]. - The company’s real estate revenue for the reporting period was CNY 973.68 million, with a gross margin of 14.65%, a decrease of 2.57 percentage points year-on-year[75]. Research and Development - The company invested 150 million yuan in R&D in 2022, representing a year-on-year increase of 16.19%[40]. - The company launched 1 new pharmaceutical product, levofloxacin eye drops, and over 100 new and upgraded cosmetic products during the reporting period[41]. - The company has established 3 national and 14 provincial research platforms, with 276 patents granted, highlighting its strong commitment to innovation and technology[58]. - The company has applied for a total of 67 new patents and received 41 patent grants during the reporting period, indicating a strong focus on innovation[129]. - The company has successfully developed a new hyaluronic acid derivative, zinc hyaluronate, and a full molecular weight HA-fullerene for its product line[128]. Market Strategy and Expansion - The company is actively developing new products, focusing on patented biological materials such as sodium hyaluronate and recombinant type III humanized collagen[36]. - The company is expanding its market presence through partnerships and participation in international exhibitions to boost sales of sodium hyaluronate[37]. - The company has established a comprehensive sales network combining domestic and international channels, including online and offline strategies[62]. - The company is transitioning from real estate to focus on pharmaceuticals and functional cosmetics, aiming to become a comprehensive operator in the health industry[167]. - The company plans to implement a "4+N" brand development strategy in the cosmetics sector to enhance brand presence and expand offline channels[170]. Corporate Governance and Management - The board of directors has held 7 meetings during the reporting period, ensuring effective governance and decision-making processes[185]. - The company has conducted 3 online performance briefings and engaged in nearly 40 investor interactions to maintain transparent communication with stakeholders[188]. - The company has implemented a robust insider information management system to protect investor rights and ensure compliance with relevant regulations[188]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[189]. Risks and Challenges - The company is facing risks related to project planning adjustments and low-margin product sales in the health real estate sector[9]. - The company is facing significant policy risks due to ongoing reforms in the pharmaceutical and cosmetics industries, which may impact operational models and competitive landscapes[176]. - Following the divestiture of its real estate business, the company's revenue structure will shift significantly, potentially leading to performance volatility and profit realization risks[181]. Future Outlook - The pharmaceutical industry is expected to maintain rapid growth, driven by aging population and increasing healthcare awareness, presenting significant market opportunities[162]. - The cosmetics market in China is projected to grow at a compound annual growth rate of 11.47%, reaching a market size of 907.61 billion RMB by 2025[163]. - The company plans to focus on the pharmaceutical market, leveraging its competitive advantages in the modern healthcare industry[162]. - The company aims to increase R&D investment and accelerate the development of new products, with a focus on green and intelligent manufacturing transformation[171].

具体数据详见《鲁商健康产业发展股份有限公司 2022 年年度报告》。 特此公告。 鲁商健康产业发展股份有限公司董事会 2023 年 3 月 31 日 证券代码：600223 证券简称：鲁商发展 编号：临 2023-011 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2022 年 10-12 月，公司房地产项目实现签约金额 11.26 亿元，同比减少 61.20%；1-12 月实现签约金额 67.38 亿元，同比减少 53.99%。2022 年 10-12 月 实现签约面积 10.38 万平方米，同比减少 63.17%；1-12 月实现签约金额面积 63.50 万平方米，同比减少 53.68%。2022 年 10-12 月无新开工；1-12 月新开工 面积 48.89 万平方米，同比减少 64.51%。2022 年 10-12 月竣工面积 12.12 万平 方米，同比减少 73.43%；1-12 月竣工面积 124.56 万平方米，同比增加 8.57%。 上述签约及新开工数据较上年同期减少主要是由于房地产市场下行及公司 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥3,693,939,070.78, representing a year-on-year increase of 61.89%[7] - The net profit attributable to shareholders for Q3 2022 was -¥35,428,385.95, a decrease of 118.45% compared to the same period last year[7] - The net cash flow from operating activities for Q3 2022 was ¥339,801,052.18, down 75.02% year-on-year[7] - The basic earnings per share for Q3 2022 was -¥0.04, a decline of 121.05% compared to the same period last year[11] - For the first nine months of 2022, the company achieved operating revenue of RMB 8.529 billion and a net profit attributable to the parent company of RMB 154 million[23] - The company's total revenue for the first three quarters of 2022 reached ¥8.53 billion, representing a significant increase of 34.4% compared to ¥6.35 billion in the same period of 2021[39] - The company's operating profit for the first three quarters of 2022 was approximately ¥391.55 million, a decrease of 42.1% compared to ¥674.86 million in the same period of 2021[42] - Total profit for the first three quarters of 2022 was approximately ¥355.23 million, down 44.7% from ¥642.40 million in 2021[42] - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was approximately ¥153.77 million, a decline of 69.5% compared to ¥503.15 million in 2021[42] - Basic earnings per share for the first three quarters of 2022 were ¥0.15, down 70% from ¥0.50 in the same period of 2021[44] - The company reported a total comprehensive income of approximately ¥185.85 million for the first three quarters of 2022, down 62.6% from ¥496.57 million in 2021[42] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥59,610,838,521.61, a decrease of 2.94% from the end of the previous year[11] - As of September 30, 2022, total assets amounted to RMB 59.611 billion, with net assets attributable to the parent company at RMB 4.038 billion[23] - The company's long-term borrowings decreased to ¥3.20 billion from ¥3.75 billion, a reduction of approximately 14.7%[35] - The total liabilities as of September 30, 2022, were ¥53.68 billion, down from ¥54.92 billion at the end of 2021, indicating a decrease of about 2.3%[35] - The company's cash and cash equivalents decreased to ¥688.77 million from ¥730.25 million, a decline of approximately 5.7%[32] - The company reported a decrease in accounts payable to ¥7.17 billion from ¥7.47 billion, a reduction of about 4.0%[35] - The company’s deferred income tax assets increased to ¥111.55 million from ¥101.25 million, reflecting a growth of approximately 10.1%[32] - The total equity attributable to shareholders decreased to ¥4.04 billion from ¥4.73 billion, a decline of approximately 14.6%[35] Revenue Segmentation - The increase in operating revenue for Q3 2022 was mainly due to increased health real estate settlements and cosmetic sales[14] - In the health real estate sector, the company recorded a signed amount of RMB 5.612 billion and a signed area of 531,300 square meters during the first nine months of 2022[23] - The cosmetics segment generated revenue of RMB 1.429 billion with a gross margin of 58.56% in the same period[24] - The pharmaceutical segment reported revenue of RMB 337 million with a gross margin of 52.32% for the first nine months of 2022[24] - The raw materials and derivatives segment achieved revenue of RMB 232 million with a gross margin of 32.47%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,127[15] - The company’s major shareholder, Shandong Commercial Group, holds 524,739,200 shares, with a total of 93 million shares pledged[20] Strategic Initiatives - The company is actively transforming from real estate to the health industry, focusing on reducing inventory and ensuring delivery[23] - The company launched a skin microbiome scientific skincare platform and collaborated with a well-known IP for a co-branded product[24] - The company is in the process of transferring a 31.5% stake in Yangzhou Lusu Health Industry Development Co., Ltd., which will no longer be included in the consolidated financial statements after the transfer[26] Cash Flow Analysis - Cash flow from operating activities for the first three quarters of 2022 was approximately ¥1.23 billion, a decrease of 74.5% compared to ¥4.80 billion in 2021[46] - Cash inflow from investment activities for the first three quarters of 2022 was approximately ¥144.95 million, a slight increase from ¥137.32 million in 2021[48] - Cash outflow from financing activities for the first three quarters of 2022 was approximately ¥11.28 billion, an increase from ¥10.12 billion in 2021[48] - The net cash flow from financing activities for the first three quarters of 2022 was approximately -¥1.53 billion, an improvement from -¥5.46 billion in 2021[48] - The company's cash and cash equivalents at the end of the first three quarters of 2022 were approximately ¥1.85 billion, an increase from ¥1.71 billion at the end of 2021[48]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately RMB 4.84 billion, an increase of 18.88% compared to RMB 4.07 billion in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 39.18% to approximately RMB 189.20 million from RMB 311.10 million in the previous year[21]. - The basic earnings per share for the first half of 2022 was RMB 0.19, down 38.71% from RMB 0.31 in the same period last year[23]. - The total assets at the end of the reporting period were approximately RMB 61.73 billion, a slight increase of 0.51% from RMB 61.42 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 2.26% to approximately RMB 4.62 billion from RMB 4.73 billion at the end of the previous year[21]. - The weighted average return on net assets for the first half of 2022 was 4.00%, a decrease of 3.34 percentage points from 7.34% in the same period last year[26]. - The company achieved a revenue of 4.835 billion CNY in the first half of 2022, representing a year-on-year growth of 18.88%[54]. - The net profit attributable to the parent company was 189 million CNY, a decrease of 39.18% year-on-year[54]. - The company’s total assets reached 61.731 billion CNY, with a net asset attributable to the parent company of 4.620 billion CNY, reflecting a growth of 0.51% and a decline of 2.26% respectively compared to the beginning of the period[54]. Operational Challenges - The net cash flow from operating activities decreased by 74.20%, primarily due to reduced sales collections in the health real estate sector influenced by market conditions[27]. - The company faced increased financial expenses due to interest capitalization from temporarily halted health real estate projects[26]. - The overall gross margin decreased year-on-year due to the impact of the pandemic and market downturn[26]. - The health real estate segment recorded a contract sales amount of 3.98 billion CNY, with a sales area of 372,000 square meters, down 56.05% and 55.02% year-on-year due to the downturn in the real estate industry[54]. - The company experienced a decline in sales collection compared to the previous year, posing challenges to its financing and operational capabilities[106]. Strategic Initiatives - The company plans to strengthen product promotion, which has led to an increase in sales expenses[26]. - The company is transitioning from a developer to a lifestyle service provider, focusing on health real estate and wellness services, with operations in multiple cities including Jinan and Qingdao[34]. - The company aims to expand its biopharmaceutical segment by increasing investment in traditional Chinese medicine innovation and developing a MAH platform[66]. - The company plans to enhance its health real estate segment by focusing on cash flow stability and project sales acceleration[65]. - The company is exploring new strategies in public infrastructure and affordable rental housing to accelerate its asset-light transformation[65]. Market Trends - The biopharmaceutical sector is experiencing a shift towards health-centered approaches, with new opportunities arising from policies supporting traditional Chinese medicine[38]. - The market for hyaluronic acid is expected to grow significantly due to rising consumer demand and policy support, indicating a broad development space ahead[39]. - The demand for biological food additives is increasing as consumers become more aware of food safety, leading to a trend of replacing chemical preservatives[41]. Product Development - The company has launched a series of hyaluronic acid-based food products, expanding its product matrix significantly since 2021[46]. - The company has developed a strong brand matrix in the biopharmaceutical sector, with notable brands such as "施沛特" and "明仁" recognized in the orthopedic field[48]. - The company has established 3 national-level and 13 provincial-level R&D platforms, with 243 authorized patents and significant achievements in hyaluronic acid research[47]. - The company launched 108 new cosmetic products and obtained 45 new authorized patents, bringing the total to 243 patents[62]. - The company’s new product ratio increased to 10% while maintaining growth in existing popular products[58]. Environmental Responsibility - The company’s subsidiaries are listed as key pollutant discharge units, indicating a focus on environmental responsibility[123]. - The company invested approximately CNY 2.963 million in environmental protection measures during the first half of 2022[136]. - The company has established a wastewater treatment station that meets discharge standards, utilizing aerobic and anaerobic treatment processes[137]. - The company has committed to continuous improvement in environmental protection capabilities among its personnel[136]. - The company has developed emergency response plans for potential environmental pollution incidents, which have been reviewed by internal and external experts[141]. Corporate Governance - The company reported a 59.29% shareholder attendance at the 2021 annual general meeting, with 598,366,887 shares represented[112]. - The company appointed new executives, including a new chairman and CFO, to support its strategic transformation[113][117]. - The company did not propose any profit distribution or capital reserve increase for the half-year period[120]. - The company has no significant litigation or arbitration matters during the reporting period[163]. - The company has not faced any non-compliance issues or penalties involving its directors, supervisors, or senior management[163].

Financial Performance - The company's operating revenue for Q1 2022 was ¥1,482,210,648.61, representing a decrease of 13.08% compared to the same period last year[5] - The net profit attributable to shareholders was ¥66,295,134.64, down 22.74% year-on-year[5] - Basic earnings per share were ¥0.07, reflecting a decrease of 17.67%[5] - Net profit for Q1 2022 was ¥66,403,453.14, a decline of 28.49% from ¥92,736,542.99 in Q1 2021[40] - Earnings per share for Q1 2022 were ¥0.07 (basic) and ¥0.06 (diluted), compared to ¥0.085 for both in Q1 2021[40] - The company reported a total comprehensive income of ¥66,403,453.14 for Q1 2022, down from ¥92,736,542.99 in Q1 2021[40] Cash Flow - The net cash flow from operating activities was negative at ¥349,836,200.78, a decline of 240.73% compared to the previous year[5] - Cash flow from operating activities for Q1 2022 was -349,836,200.78, a decrease from 248,589,677.72 in Q1 2021, indicating a significant decline in operational cash generation[44] - Cash received from sales of goods and services in Q1 2022 was 1,849,433,506.50, down from 3,571,795,540.77 in Q1 2021, highlighting a decline in revenue generation[44] - Cash outflow for purchasing goods and services in Q1 2022 was 1,804,188,418.62, a decrease from 2,663,352,605.31 in Q1 2021, suggesting cost management efforts[44] - Cash received from other operating activities in Q1 2022 was 392,427,510.28, up from 293,837,502.80 in Q1 2021, indicating improved operational efficiency[44] - Net cash flow from financing activities for Q1 2022 was 375,034,442.92, a recovery from -1,293,164,502.63 in Q1 2021, reflecting improved financing conditions[45] - The company received 1,439,396,311.79 in cash from other financing activities in Q1 2022, significantly higher than 654,624,177.93 in Q1 2021, indicating enhanced financing activities[45] Assets and Liabilities - The total assets at the end of the reporting period were ¥61,638,844,811.82, showing a slight increase of 0.36% from the previous year[8] - The company’s total liabilities as of March 31, 2022, were CNY 55.02 billion, compared to CNY 55.34 billion at the end of 2021[32] - Total liabilities as of March 31, 2022, were ¥55,090,016,431.00, slightly up from ¥54,915,669,576.75 as of December 31, 2021[33] - The company’s equity attributable to shareholders was CNY 4.78 billion as of March 31, 2022, compared to CNY 4.77 billion at the end of 2021[24] - Total equity attributable to shareholders as of March 31, 2022, was ¥4,775,079,191.66, an increase from ¥4,727,128,835.89 as of December 31, 2021[33] Segment Performance - The pharmaceutical segment reported revenue of CNY 90 million in Q1 2022, a decrease of 25.74% year-on-year, with a gross margin of 55.46%[23] - The cosmetics segment saw significant growth, with revenue reaching CNY 419 million in Q1 2022, a year-on-year increase of 95.31% and a gross margin of 61.56%[22] - The health real estate segment experienced a decline, with a signed contract amount of CNY 777 million in Q1 2022, down 75.6% year-on-year[19] - The decrease in net profit was mainly due to a reduction in real estate business revenue[10] - The company’s non-real estate business revenue is steadily increasing, with new projects in construction management and commercial management expanding its portfolio[22] Research and Development - Research and development expenses for Q1 2022 were ¥22,342,527.54, a slight decrease from ¥23,263,647.47 in Q1 2021[39] - The company received government subsidies amounting to ¥7,738,651.98, primarily related to pharmaceutical research and development[8] Strategic Direction - The company plans to continue its strategic transformation towards the health industry, moving away from real estate[19]

Financial Performance - The company achieved a net profit attributable to shareholders of 361,900,881.01 RMB for the year 2021, with the parent company reporting a net profit of 351,504,529.99 RMB[6]. - The company's operating revenue for 2021 was approximately ¥12.36 billion, a decrease of 9.20% compared to 2020[27]. - Net profit attributable to shareholders for 2021 was approximately ¥361.90 million, down 43.34% year-on-year[30]. - The total profit for 2021 was 644 million RMB, down 24.58% compared to the previous year[80]. - Net profit attributable to the parent company was 362 million RMB, reflecting a significant decline of 43.34% year-on-year[80]. - The total assets at the end of 2021 were approximately ¥61.42 billion, a slight decrease of 0.14% from the previous year[27]. - The weighted average return on equity for 2021 was 8.34%, a decrease of 11.69 percentage points from 2020[30]. - The basic earnings per share for 2021 was ¥0.36, a decrease of 43.75% compared to 2020[30]. Dividend and Profit Distribution - The proposed cash dividend distribution is 1.1 RMB per 10 shares, totaling 111,006,741.89 RMB, with 303,331,957.80 RMB available for distribution to shareholders[6]. - The company has a remaining undistributed profit of 192,325,215.91 RMB to be carried forward to future years[6]. - The company is committed to sustainable development and shareholder returns as part of its profit distribution strategy[6]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements related to future strategies and financial conditions[7]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[8]. - The company has not violated decision-making procedures for external guarantees[10]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The audit report issued by Da Xin Accounting Firm is a standard unqualified opinion[5]. Business Operations and Revenue Streams - The company achieved a contract sales amount of ¥14.645 billion in 2021, a decrease of 16.78% year-on-year, with a sales area of 1.3711 million square meters, down 18.19%[39]. - The company completed new construction of 1.3775 million square meters in 2021, a decrease of 26.78% compared to the previous year[39]. - The company expanded its property management operations, managing approximately 22.87 million square meters by the end of 2021[39]. - The company actively developed light asset businesses, including health care and commercial management, and secured multiple government and market construction projects[39]. Cosmetics and Pharmaceutical Segments - In 2021, the cosmetics business achieved revenue of 1.495 billion yuan, a year-on-year increase of 117.01%[40]. - The medical segment reported revenue of 541 million yuan, reflecting a year-on-year growth of 8.71%[43]. - The raw materials and additives segment generated revenue of 241 million yuan, with a year-on-year increase of 21.96%[43]. - The total revenue for the pharmaceutical group reached 2.181 billion yuan, accounting for 17.64% of the company's total revenue, an increase of 8.03 percentage points from the previous year[43]. - The net profit attributable to the parent company was 180 million yuan, representing 49.68% of the total net profit, a year-on-year growth of 33.05%[43]. Research and Development - The company established three new research centers in collaboration with universities, enhancing its R&D capabilities[49]. - The company has been awarded 197 patents and has undertaken over 30 major national and provincial scientific projects, showcasing its strong R&D strength[75]. - The company has initiated six R&D projects in health real estate, enhancing product quality and competitiveness[113]. - The company completed nearly 300 safety and efficacy evaluations for its raw materials in compliance with new regulations[171]. Market Trends and Strategic Initiatives - The health industry operation sector benefits from China's economic growth, urbanization, and rising consumer income, creating strong demand for property services[53]. - The cosmetics market in China reached a size of CNY 367.8 billion in the first 11 months of 2021, with a growth rate of 15.3%[55]. - The introduction of strong regulatory measures in the cosmetics sector is expected to benefit legitimate companies, enhancing market competitiveness[55]. - The company aims to transform from a real estate developer to a lifestyle service provider, focusing on creating better living experiences[61]. Sales and Marketing - The company's online cosmetic sales increased significantly, with revenue of CNY 1,396,293,394.30, reflecting a 144.84% year-over-year growth[1]. - The brand Yilian achieved sales of over 15 million bottles of its hyaluronic acid moisturizing spray in 2021, ranking first in the category on Tmall and winning the Tmall Golden Makeup Award[159]. - The brand Aier Doctor's four key products accounted for approximately 70% of total sales in 2021, with the new product "Anti-Gravity Water Emulsion" exceeding 10 million in sales within months of launch[161]. - The company plans to continue expanding its direct sales and online presence to enhance revenue growth in the cosmetics segment[93]. Investment and Financing - The company secured strategic investments totaling 738 million yuan, setting a record for state-owned enterprises in Shandong Province[45]. - The total financing amount at the end of the period was RMB 1,939.94 million, with an average financing cost of 9.975%[150]. - The company financed RMB 5.45 billion from non-related parties and RMB 381,400 from related parties during the reporting period, both within the authorized limits set by the shareholders' meeting[150]. Land and Development Projects - The company holds a total of 1,000,000 square meters of land for development across various regions, with a significant portion in Qingdao at 247,793 square meters[139]. - The planned construction area for the projects in Qingdao includes 639,981 square meters, indicating a strong focus on residential and commercial developments[140]. - The company has reported a total of 1,000,000,000 RMB in investments across multiple projects in Qingdao, showcasing its strategic focus on this key market[140].

证券代码：600223 证券简称：鲁商发展 编号：临 2021-059 鲁商健康产业发展股份有限公司 关于参加山东辖区上市公司 2021 年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为加强与投资者之间的沟通交流，提高上市公司透明度和治理水平，鲁商健 康产业发展股份有限公司（以下简称"公司"）将参加由山东证监局、山东上市 公司协会联合举办的"山东辖区上市公司 2021 年度投资者网上集体接待日"活 动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可登陆"全景·路演天下"网站（http://rs.p5w.net/) 参与公司此次投资者网上集体接待日活动，时间为 2021 年 11 月 16 日（周二） 14：00-16：00。 届时公司董事会秘书李璐女士、财务总监杨云龙先生、证券事务代表代玮玉 女士将参与本次投资者网上集体接待日活动，与投资者进行在线交流，欢迎广大 投资者积极参与。 特此公告。 鲁商健康产业发展股份有限 ...

Financial Performance - The company's operating revenue for Q3 2021 was ¥2,281,769,622.97, a decrease of 34.60% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2021 was ¥192,056,196.93, an increase of 11.00% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥197,826,094.46, reflecting a 19.10% increase compared to the previous year[5]. - The basic earnings per share for Q3 2021 was ¥0.19, up by 11.76% from the same period last year[5]. - For the first nine months of 2021, the company achieved operating revenue of CNY 6.349 billion, a year-on-year decrease of 9.75%, while net profit attributable to the parent company was CNY 503 million, an increase of 21.90%[17]. - The company reported a net profit of CNY 2,219,776,200.30 for the first three quarters of 2021, compared to CNY 1,977,690,578.91 in the same period of 2020, indicating a growth of 12.24%[38]. - Net profit for the first three quarters of 2021 was ¥496,566,708.16, compared to ¥461,757,402.41 in 2020, indicating an increase of about 7.5%[42]. - The total profit for the first three quarters of 2021 was ¥642,404,193.40, slightly higher than ¥633,337,852.75 in 2020, reflecting a growth of approximately 1.6%[42]. - Basic earnings per share for the first three quarters of 2021 were ¥0.50, compared to ¥0.41 in the same period of 2020, marking an increase of 21.9%[44]. Assets and Liabilities - The total assets at the end of the reporting period were ¥63,628,537,354.90, an increase of 3.46% compared to the end of the previous year[8]. - As of September 30, 2021, the company reported total assets of CNY 63.629 billion, with net assets attributable to the parent company at CNY 4.326 billion, reflecting growth of 3.46% and 6.02% respectively since the beginning of the year[17]. - The total liabilities as of September 30, 2021, were CNY 57,446,512,828.44, compared to CNY 54,981,173,661.44 at the end of 2020, indicating an increase of 8.48%[38]. - The equity attributable to shareholders of the parent company increased to CNY 4,325,768,512.82 as of September 30, 2021, from CNY 4,080,050,127.32 at the end of 2020, reflecting a rise of 6.02%[38]. - The company's total liabilities increased by CNY 4,465,339,167.00 from the end of 2020 to September 30, 2021, reflecting a significant rise in financial obligations[35]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥4,803,700,841.44, showing a significant increase of 209.62%[5]. - Cash flow from operating activities for the first three quarters of 2021 was ¥4,803,700,841.44, significantly higher than ¥1,551,488,268.89 in 2020, showing an increase of approximately 209.5%[47]. - The net cash flow from investment activities for the first three quarters of 2021 was -¥273,222,403.57, compared to -¥100,095,270.36 in 2020, indicating a worsening of investment cash flow[48]. - The company experienced a credit impairment loss of -¥45,715,780.80 in the first three quarters of 2021, contrasting with a gain of ¥30,961,529.35 in 2020[42]. - The company's short-term borrowings rose to CNY 4,499,674,450.03 as of September 30, 2021, up from CNY 4,303,297,457.12 at the end of 2020, an increase of 4.56%[35]. Segment Performance - The health real estate segment recorded a signed amount of CNY 11.744 billion, up 11.05% year-on-year, but operating revenue decreased by 25.80% to CNY 4.250 billion, with a gross margin of 22.23%[17]. - The cosmetics segment saw operating revenue of CNY 999 million, a significant increase of 174.58% year-on-year, with a gross margin of 63.21%[20]. - The pharmaceutical segment reported operating revenue of CNY 396 million, up 22.14% year-on-year, with a gross margin of 58.32%[20]. - The raw materials and additives segment achieved operating revenue of CNY 176 million, reflecting a year-on-year growth of 35.26%, with a gross margin of 40%[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 57,075[12]. - The largest shareholder, Shandong Commercial Group Co., Ltd., held 52.00% of the shares[12]. - The company’s major shareholder, Shandong Commercial Group, holds 52.00% of the total shares, with 50.02% held through its own account and 1.98% through a pledged account[16]. Strategic Initiatives - The company plans to introduce strategic investors through a public offering for its wholly-owned subsidiary, Shandong Furuida Biotechnology Co., Ltd., with the offering period from September 24 to November 23, 2021[23]. - The company adjusted the exercise price of its stock option incentive plan, reducing it from CNY 2.67 to CNY 2.47 per share for the first grant[22].

Financial Performance - The company's operating revenue for the first half of 2021 was RMB 4,067,445,394.22, an increase of 14.69% compared to RMB 3,546,345,476.12 in the same period last year[25]. - The net profit attributable to shareholders of the listed company reached RMB 311,097,124.53, reflecting a growth of 29.76% from RMB 239,742,511.17 year-on-year[25]. - The net cash flow from operating activities was RMB 3,443,553,610.16, a significant improvement compared to a negative cash flow of RMB -52,334,530.38 in the previous year[25]. - The company's net assets attributable to shareholders at the end of the reporting period were RMB 4,152,464,134.25, up 1.77% from RMB 4,080,050,127.32 at the end of the previous year[25]. - The total assets increased by 2.08% to RMB 62,775,587,719.39 from RMB 61,498,584,742.77 year-on-year[25]. - Basic earnings per share for the first half of 2021 were RMB 0.31, a 29.17% increase from RMB 0.24 in the same period last year[26]. - The company reported a total non-operating income of CNY 1,492,692.43, a decrease of 85.0% compared to CNY 9,909,739.21 in the same period last year[30]. Revenue Growth by Sector - The company reported a 210.30% increase in cosmetics revenue due to enhanced online promotional efforts[26]. - Pharmaceutical sales revenue increased by 45.36% as a result of expanded sales channels post-pandemic[26]. - The net cash inflow from health real estate sales increased by RMB 2,424,000,000, a growth of 43.43%[27]. - The net cash inflow from pharmaceutical and cosmetics sales rose by RMB 759,000,000, marking a 124.72% increase[27]. - The health real estate segment achieved a contract sales amount of 9.055 billion yuan, with a year-on-year increase of 26.34%[52]. - The biopharmaceutical segment reported a revenue of 949 million yuan, with a year-on-year growth of 114.29%[52]. Investment and Development - The company has developed over 40 ecological health projects across various cities, focusing on health real estate and infrastructure development[35]. - The company has established partnerships with renowned universities and research institutions, leading to the development of 156 authorized patents[39]. - The company has established a comprehensive health ecosystem, including high-end elderly care institutions and community health stations[44]. - The company has introduced over ten functional food products that combine traditional Chinese medicine with new functional factors, launching them on various online platforms[136]. - The company has established nearly 10 demonstration bases for traditional Chinese medicine cultivation, focusing on standardized planting and intelligent manufacturing[123]. Marketing and Brand Strategy - The company launched 31 new cosmetic products, including fullerene hyaluronic acid essence, enhancing its product portfolio in the beauty sector[56]. - The company implemented new marketing strategies, including CPS promotion, to enhance brand visibility and sales growth[76]. - The company aims to build a multi-brand development strategy in the cosmetics sector, focusing on high-quality niche markets and enhancing market share[132]. - The company reported a significant increase in brand awareness and exposure during the fifth China Brand Day event[131]. Environmental and Social Responsibility - The company invested approximately 507,000 yuan in environmental protection measures in the first half of 2021[158]. - The company’s environmental protection facilities operated normally, ensuring compliance with pollutant discharge standards[158]. - The company has raised over 1.2 million yuan for the "Warm Heart·Public Welfare" project, building 75 "Hope Houses" for children[171]. - The company has actively participated in the "Waste-Free Society" initiative in various business sectors, promoting sustainable development[170]. Challenges and Strategic Focus - The pharmaceutical sector is facing pressure due to price declines from centralized procurement, prompting companies to enhance their supply chain management[36]. - The company is focusing on cash flow management and risk mitigation strategies in response to tightening market regulations and financial risks[119]. - The company aims to deepen organizational reform and enhance management systems to support its transformation into a leading health industry operator[57]. - The company is committed to increasing R&D investment to maintain innovation and competitive advantages in the face of rising industry concentration[119]. Related Party Transactions - The total amount of related party debts at the end of the reporting period is RMB 10,579,435,345.09, with a decrease of RMB 434,693,615.84 during the period[193]. - The company’s related party transactions include a beginning balance of RMB 7,385,749,244.64 with Shandong Commercial Group Co., Ltd., increasing to RMB 7,541,026,497.13 by the end of the period[190]. - The company has committed to maintaining business independence and reducing related party transactions to protect the interests of all shareholders[178].

[Important Notice](index=3&type=section&id=Item%201.%20Important%20Notice) The company's board, supervisory board, and senior management guarantee the report's authenticity, accuracy, and completeness, with all directors attending the review meeting and the report being unaudited [Report Authenticity and Audit Status](index=3&type=section&id=1.1%20Report%20Authenticity%20and%20Audit%20Status) The company's board, supervisory board, and senior management guarantee the report's authenticity, accuracy, and completeness, with all directors attending the review meeting and the report being unaudited - The company's board of directors, supervisory board, and senior management guarantee the quarterly report's content is true, accurate, and complete, free from false records, misleading statements, or major omissions[7](index=7&type=chunk) - All company directors attended the board meeting to review the quarterly report[8](index=8&type=chunk) - This company's first-quarter report is unaudited[10](index=10&type=chunk) [Company Profile](index=3&type=section&id=Item%202.%20Company%20Profile) This section provides an overview of the company's key financial performance and shareholder structure at the end of the reporting period [Key Financial Data](index=3&type=section&id=2.1%20Key%20Financial%20Data) The company demonstrated strong financial performance in Q1 2021, with revenue growing by 21.32% and net profit attributable to shareholders increasing by 37.25%, alongside a positive shift in net operating cash flow Key Financial Data for Q1 2021 (Consolidated Statements) | Indicator | End of Current Period/Year-to-Date | End of Prior Year/Prior Year-to-Date | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets (CNY) | 62,269,432,977.00 | 61,498,584,742.77 | 1.25 | | Net Assets Attributable to Shareholders (CNY) | 4,147,318,254.85 | 4,080,050,127.32 | 1.65 | | Net Cash Flow from Operating Activities (CNY) | 248,589,677.72 | -1,015,130,298.61 | N/A | | Operating Revenue (CNY) | 1,705,274,995.79 | 1,405,641,084.71 | 21.32 | | Net Profit Attributable to Shareholders (CNY) | 85,803,103.50 | 62,513,808.27 | 37.25 | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) (CNY) | 83,147,559.79 | 59,686,756.38 | 39.31 | | Weighted Average Return on Net Assets (%) | 2.09 | 2.25 | decreased by 0.16 percentage points | | Basic Earnings Per Share (CNY/share) | 0.085 | 0.06 | 41.67 | | Diluted Earnings Per Share (CNY/share) | 0.085 | 0.06 | 41.67 | Non-Recurring Gains and Losses Items and Amounts | Item | Amount for Current Period (CNY) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | 8,753.41 | | Government Grants Included in Current Profit/Loss | 4,121,100.30 | | Gains/Losses from Fair Value Changes and Investment Income | 35,295.84 | | Other Non-Operating Income and Expenses | 89,306.66 | | Impact of Minority Interests (After Tax) | -1,003,489.33 | | Income Tax Impact | -595,423.17 | | Total | 2,655,543.71 | [Shareholder Information at Report End](index=4&type=section&id=2.2%20Shareholder%20Information%20at%20Report%20End) As of the reporting period end, the company had 62,538 shareholders, with Shandong Commercial Group Co., Ltd. as the largest shareholder at 52.00%, and some top ten shareholders having related party relationships or ongoing share reduction plans - Total shareholders (households) were **62,538**[14](index=14&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shares Held at Period End (shares) | Proportion (%) | Number of Restricted Shares Held (shares) | Share Status | Pledged or Frozen Shares (shares) | Shareholder Nature | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Shandong Commercial Group Co., Ltd. | 524,739,200 | 52.00 | 0 | Unrestricted | 0 | State-owned Legal Person | | Boshan Wantongda Construction and Installation Company | 19,500,000 | 1.93 | 0 | Pledged | 19,500,000 | Domestic Non-State-owned Legal Person | | LUSHANG Group Co., Ltd. | 17,210,000 | 1.71 | 0 | Unrestricted | 0 | State-owned Legal Person | | Zibo City Asset Management Co., Ltd. | 12,156,250 | 1.20 | 0 | Unrestricted | 0 | State-owned Legal Person | | Shanghai Fangda Investment Management Co., Ltd. | 10,180,000 | 1.01 | 0 | Unrestricted | 0 | Unknown | | Shandong World Trade Center | 9,836,000 | 0.97 | 0 | Unrestricted | 0 | State-owned Legal Person | | Jin Yude | 5,870,000 | 0.58 | 0 | Unrestricted | 0 | Unknown | | Zibo Fifth Cotton Textile Factory | 5,590,000 | 0.55 | 0 | Pledged | 5,590,000 | Domestic Non-State-owned Legal Person | | Hong Kong Securities Clearing Company Limited | 4,727,961 | 0.47 | 0 | Unrestricted | 0 | Unknown | | He Zengmao | 4,587,965 | 0.45 | 0 | Unrestricted | 0 | Unknown | - Shandong Commercial Group Co., Ltd., LUSHANG Group Co., Ltd., and Shandong World Trade Center have related party relationships; Boshan Wantongda Construction and Installation Company and Zibo Fifth Cotton Textile Factory also have related party relationships[17](index=17&type=chunk) - Shandong World Trade Center is executing a centralized bidding share reduction plan[17](index=17&type=chunk) [Significant Events](index=5&type=section&id=Item%203.%20Significant%20Events) This section details significant changes in financial statement items, the progress of important corporate events, and any unfulfilled commitments or profit warnings [Significant Changes in Key Financial Statement Items and Indicators, and Their Reasons](index=5&type=section&id=3.1%20Significant%20Changes%20in%20Key%20Financial%20Statement%20Items%20and%20Indicators%2C%20and%20Their%20Reasons) During the reporting period, the company experienced significant changes in several financial indicators, including a 101.70% increase in sales expenses due to reduced promotions last year, a 92.31% rise in R&D expenses from increased project investment, and a 61.12% decrease in financial expenses due to loan repayments, with net operating cash flow turning positive from increased sales collections Changes in Key Financial Statement Items | Item Name | Amount at Period End/Current Period (CNY) | Amount at Prior Period End/Prior Period (CNY) | Change Amount (CNY) | Change (%) | Explanation | | :--- | :--- | :--- | :--- | :--- | :--- | | Receivables Financing | 40,505,630.35 | 256,811,240.51 | -216,305,610.16 | -84.23 | Primarily due to endorsement and discounting of bills | | Employee Remuneration Payable | 73,550,411.14 | 114,041,764.27 | -40,491,353.13 | -35.51 | Primarily due to decreased unpaid remuneration at period end | | Selling Expenses | 211,985,408.97 | 105,101,667.38 | 106,883,741.59 | 101.70 | Primarily due to reduced promotional activities in the prior period affected by the pandemic | | Administrative Expenses | 85,684,794.29 | 64,353,915.87 | 21,330,878.42 | 33.15 | Primarily due to increased expenses from information technology construction in the current period | | Research and Development Expenses | 23,263,647.47 | 12,096,923.78 | 11,166,723.69 | 92.31 | Primarily due to increased investment in R&D projects in the current period | | Financial Expenses | 3,852,868.46 | 9,910,557.27 | -6,057,688.81 | -61.12 | Primarily due to decreased interest expenses from loan repayments | | Credit Impairment Losses | -4,511,627.02 | 5,846,900.30 | -10,358,527.32 | -177.16 | Primarily due to provision for bad debts on receivables in accordance with accounting policies | | Net Cash Flow from Operating Activities | 248,589,677.72 | -1,015,130,298.61 | 1,263,719,976.33 | N/A | Primarily due to increased sales collections in the current period | | Net Cash Flow from Investing Activities | -59,264,663.34 | -287,249,541.34 | 227,984,878.00 | N/A | Primarily due to fewer investment payments in the prior period | | Net Cash Flow from Financing Activities | -1,293,164,502.63 | 1,790,156,163.90 | -3,083,320,666.53 | -172.24 | Primarily due to higher financing in the prior period | [Progress of Significant Events, Their Impact, and Analysis of Solutions](index=6&type=section&id=3.2%20Progress%20of%20Significant%20Events%2C%20Their%20Impact%2C%20and%20Analysis%20of%20Solutions) The company completed the listing of shares from its 2018 stock option incentive plan, adjusted its registered capital, and a subsidiary acquired land for rural revitalization tourism, while also holding an investor performance briefing - **321,296 shares** from the company's stock option plan were registered and listed for trading on January 19, 2021[22](index=22&type=chunk) - The company's total share capital increased from **1,000,968,000 shares** to **1,009,152,199 shares**, with registered capital changing to **CNY 1,009,152,199**, and industrial and commercial registration completed[24](index=24&type=chunk) - The wholly-owned subsidiary Shandong LUSHANG Real Estate Co., Ltd.'s joint venture, Taishan You Rural Revitalization Ecological Tourism Development (Shandong) Co., Ltd., successfully bid for **151,560 square meters** of state-owned construction land use rights in Tai'an City for a total transaction price of **CNY 356.61 million**[25](index=25&type=chunk) - The company held its 2020 annual performance briefing via the SSE Roadshow Center, engaging with investors on annual performance and operating conditions[25](index=25&type=chunk) [Overdue Unfulfilled Commitments During the Reporting Period](index=7&type=section&id=3.3%20Overdue%20Unfulfilled%20Commitments%20During%20the%20Reporting%20Period) The company had no overdue unfulfilled commitments during the reporting period - There were no overdue unfulfilled commitments during the reporting period[26](index=26&type=chunk) [Warning and Explanation of Potential Cumulative Net Profit Loss or Significant Change from Prior Year-End to Next Reporting Period End](index=7&type=section&id=3.4%20Warning%20and%20Explanation%20of%20Potential%20Cumulative%20Net%20Profit%20Loss%20or%20Significant%20Change%20from%20Prior%20Year-End%20to%20Next%20Reporting%20Period%20End) The company has not issued any warnings regarding potential cumulative net profit loss or significant changes from the beginning of the year to the end of the next reporting period - The company has not issued any warnings regarding potential cumulative net profit loss or significant changes[26](index=26&type=chunk) [Appendix](index=8&type=section&id=Item%204.%20Appendix) This section contains the company's financial statements, details on the first-time adoption of new lease standards, and the audit status of the quarterly report [Financial Statements](index=8&type=section&id=4.1%20Financial%20Statements) This section provides the company's consolidated and parent company financial statements for Q1 2021, including the balance sheet, income statement, and cash flow statement, offering a comprehensive view of its financial position, operating results, and cash flows [Consolidated Balance Sheet](index=8&type=section&id=4.1.1%20Consolidated%20Balance%20Sheet) As of March 31, 2021, the company's consolidated total assets increased by 1.25% from the prior year-end, primarily driven by increases in inventory and contract liabilities, while monetary funds decreased and net assets attributable to parent company shareholders grew Key Data from Consolidated Balance Sheet | Item | March 31, 2021 (CNY) | December 31, 2020 (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Monetary Funds | 4,427,813,016.95 | 5,073,947,631.28 | -12.74 | | Inventories | 48,804,987,297.74 | 46,664,870,520.66 | 4.59 | | Total Current Assets | 59,870,018,647.41 | 59,116,788,820.88 | 1.27 | | Total Assets | 62,269,432,977.00 | 61,498,584,742.77 | 1.25 | | Contract Liabilities | 20,439,101,774.89 | 18,560,560,051.08 | 10.12 | | Total Liabilities | 55,743,669,675.72 | 54,981,173,661.44 | 1.39 | | Total Equity Attributable to Parent Company Owners | 4,147,318,254.85 | 4,080,050,127.32 | 1.65 | [Parent Company Balance Sheet](index=11&type=section&id=4.1.2%20Parent%20Company%20Balance%20Sheet) As of March 31, 2021, the parent company's total assets slightly increased due to higher other receivables, while long-term equity investments decreased and total liabilities rose from increased other payables Key Data from Parent Company Balance Sheet | Item | March 31, 2021 (CNY) | December 31, 2020 (CNY) | | :--- | :--- | :--- | | Monetary Funds | 400,370,069.33 | 427,967,057.82 | | Other Receivables | 3,156,226,745.17 | 2,998,991,263.80 | | Long-Term Equity Investments | 2,092,328,550.02 | 2,161,172,622.68 | | Total Assets | 5,674,826,766.38 | 5,613,711,549.34 | | Other Payables | 2,088,597,612.35 | 1,983,728,900.15 | | Total Liabilities | 2,712,960,417.31 | 2,631,388,924.48 | | Total Owners' Equity | 2,961,866,349.07 | 2,982,322,624.86 | [Consolidated Income Statement](index=14&type=section&id=4.1.3%20Consolidated%20Income%20Statement) In Q1 2021, the company's consolidated total operating revenue increased by 21.32%, and net profit attributable to parent company shareholders grew by 37.25%, despite significant increases in sales and R&D expenses, with investment income also contributing to profit growth Key Data from Consolidated Income Statement | Item | Q1 2021 (CNY) | Q1 2020 (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 1,705,274,995.79 | 1,405,641,084.71 | 21.32 | | Total Operating Costs | 1,575,558,636.96 | 1,300,750,231.59 | 21.13 | | Selling Expenses | 211,985,408.97 | 105,101,667.38 | 101.70 | | Research and Development Expenses | 23,263,647.47 | 12,096,923.78 | 92.31 | | Investment Income | 14,208,702.80 | 12,265,504.76 | 15.84 | | Operating Profit | 143,290,867.02 | 125,135,260.09 | 14.51 | | Net Profit | 92,736,542.99 | 65,178,478.33 | 42.28 | | Net Profit Attributable to Parent Company Shareholders | 85,803,103.50 | 62,513,808.27 | 37.25 | | Basic Earnings Per Share (CNY/share) | 0.085 | 0.06 | 41.67 | [Parent Company Income Statement](index=16&type=section&id=4.1.4%20Parent%20Company%20Income%20Statement) In Q1 2021, the parent company's net loss significantly narrowed to -CNY 1,921,299.82, primarily due to financial expenses turning into income and contributions from investment gains Key Data from Parent Company Income Statement | Item | Q1 2021 (CNY) | Q1 2020 (CNY) | | :--- | :--- | :--- | | Administrative Expenses | 13,905,740.56 | 6,779,751.91 | | Financial Expenses | -9,707,858.96 | 2,299.30 | | Investment Income | 2,170,527.34 | N/A | | Operating Profit | -1,921,299.84 | -6,782,051.21 | | Total Profit | -1,921,299.82 | -6,782,051.21 | | Net Profit | -1,921,299.82 | -6,782,051.21 | [Consolidated Cash Flow Statement](index=18&type=section&id=4.1.5%20Consolidated%20Cash%20Flow%20Statement) In Q1 2021, consolidated net cash flow from operating activities turned positive to CNY 249 million, driven by increased sales collections, while investment cash outflows decreased and net cash flow from financing activities shifted from positive to negative due to higher financing in the prior year Key Data from Consolidated Cash Flow Statement | Item | Q1 2021 (CNY) | Q1 2020 (CNY) | Change | | :--- | :--- | :--- | :--- | | Cash Received from Sales of Goods and Services | 3,571,795,540.77 | 1,880,504,637.55 | ⬆️ | | Net Cash Flow from Operating Activities | 248,589,677.72 | -1,015,130,298.61 | ⬆️ (from negative to positive) | | Net Cash Flow from Investing Activities | -59,264,663.34 | -287,249,541.34 | ⬆️ (outflow decreased) | | Net Cash Flow from Financing Activities | -1,293,164,502.63 | 1,790,156,163.90 | ⬇️ (from positive to negative) | | Net Increase in Cash and Cash Equivalents | -1,103,858,901.99 | 487,756,560.02 | ⬇️ (from positive to negative) | | Cash and Cash Equivalents at Period End | 1,536,222,968.76 | 2,136,967,131.43 | ⬇️ | [Parent Company Cash Flow Statement](index=20&type=section&id=4.1.6%20Parent%20Company%20Cash%20Flow%20Statement) In Q1 2021, the parent company's net cash flow from operating activities remained negative, but net cash flow from investing activities turned positive due to cash received from investment recovery, while net cash flow from financing activities shifted from positive to negative, reflecting increased debt repayment and dividend distribution Key Data from Parent Company Cash Flow Statement | Item | Q1 2021 (CNY) | Q1 2020 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -8,631,457.81 | 6,966,164.17 | | Net Cash Flow from Investing Activities | 37,284,980.61 | -403,383,109.23 | | Net Cash Flow from Financing Activities | -56,250,511.29 | 403,309,788.01 | | Net Increase in Cash and Cash Equivalents | -27,596,988.49 | 6,892,842.95 | | Cash and Cash Equivalents at Period End | 400,370,069.33 | 11,254,814.73 | [Adjustments to Financial Statements at the Beginning of the First Year of Adopting New Lease Standards from 2021](index=21&type=section&id=4.2%20Adjustments%20to%20Financial%20Statements%20at%20the%20Beginning%20of%20the%20First%20Year%20of%20Adopting%20New%20Lease%20Standards%20from%202021) The company adopted new lease standards from January 1, 2021, but due to its primary engagement in short-term leases, the implementation had no significant impact on the opening balances of the financial statements, financial position, operating results, or cash flows for the period - The company adopted new lease standards effective January 1, 2021[75](index=75&type=chunk) - The company's leasing activities primarily involve short-term leases, thus the adoption of new lease standards had no significant impact on the opening balances of the financial statements for the current period[76](index=76&type=chunk) - The adoption of new lease standards will not have a significant impact on the company's financial position, operating results, or cash flows[76](index=76&type=chunk) [Consolidated Balance Sheet Adjustment](index=21&type=section&id=4.2.1%20Consolidated%20Balance%20Sheet%20Adjustment) The first-time adoption of new lease standards resulted in no adjustments to the company's consolidated balance sheet between January 1, 2021, and December 31, 2020 - All items in the consolidated balance sheet show identical amounts for December 31, 2020, and January 1, 2021, with zero adjustments, indicating no significant impact of the new lease standards on the consolidated opening balances[67](index=67&type=chunk)[75](index=75&type=chunk) [Parent Company Balance Sheet Adjustment](index=24&type=section&id=4.2.2%20Parent%20Company%20Balance%20Sheet%20Adjustment) Similar to the consolidated statements, the first-time adoption of new lease standards also resulted in no adjustments to the parent company's balance sheet between January 1, 2021, and December 31, 2020 - All items in the parent company balance sheet show identical amounts for December 31, 2020, and January 1, 2021, with zero adjustments, indicating no significant impact of the new lease standards on the parent company's opening balances[77](index=77&type=chunk)[82](index=82&type=chunk) [Explanation of Retrospective Adjustment of Prior Period Comparative Data upon First Adoption of New Lease Standards from 2021](index=26&type=section&id=4.3%20Explanation%20of%20Retrospective%20Adjustment%20of%20Prior%20Period%20Comparative%20Data%20upon%20First%20Adoption%20of%20New%20Lease%20Standards%20from%202021) The company did not retrospectively adjust prior period comparative data upon the first-time adoption of new lease standards from 2021 - The company did not retrospectively adjust prior period comparative data[82](index=82&type=chunk) [Audit Report](index=26&type=section&id=4.4%20Audit%20Report) This quarterly report is unaudited, therefore no audit report is attached - This quarterly report is unaudited, and thus no audit report is provided[82](index=82&type=chunk)